| Name | Title | Contact Details |
|---|
Grabber Performance Group is a Wyoming, MI-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Beckman Coulter Genomics is a Beverly, MA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Beardsworth Consulting Group is a Flemington, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
In every industry there is a company that thinks, and does things, differently. In employee group benefits, GroupHEALTH Benefits Solutions™ is that company. GroupHEALTH is transforming the way Canadians experience benefits by developing and delivering the most affordable, configurable, and usable benefit solutions to businesses across Canada. Leaders in employee benefits plans and group insurance, the GroupHEALTH Family of Companies has more than 500 employees in offices in Vancouver, Surrey, Calgary, Edmonton, Etobicoke, Woodbridge, and Barrie. With annual premiums exceeding $500 million and over $5 billion in pension assets under management, GroupHEALTH supplies market leading employee benefit services to more than 4,000 client organizations across Canada in both the public and private sectors, supporting more than 450,000 Canadians and their families.
Versartis, Inc. (NASDAQ: VSAR) is an endocrine-focused biopharmaceutical company developing novel, long-acting medicines to transform treatment for patients with endocrine disorders. The company is led by a management team with rich experience and expertise discovering, developing and commercializing innovative therapeutics for the life sciences industry. Versartis` mission is to develop, manufacture and commercialize novel therapeutics to improve and transform treatment for patients with orphan endocrine disorders. Versartis is well-positioned to deliver a major innovation to the global growth hormone deficiency (GHD) market with the company`s most advanced clinical candidate, somavaratan. Somavaratan is a novel, long-acting form of recombinant human growth hormone that is in global late-stage clinical trials to treat GHD in children and adults. Twice-monthly somavaratan is intended to reduce the burden of daily injection therapy by requiring significantly fewer injections, potentially improving compliance/adherence and treatment outcomes.